entecavir
J - Antiinfectives For Systemic Use -> J05 - Antivirals For Systemic Use -> J05A - Direct Acting Antivirals -> J05AF - Nucleoside And Nucleotide Reverse Transcriptase Inhibitors -> J05AF10 - Entecavir
Administration category:
Free
Medicine group:
antiviral
Brand name:
Baraclude
Safety margins
| Weight | ROA | Dosage |
|---|---|---|
|
ROA: po |
Dosage: min. 0.5mg 1 dd to max. 1mg 1 dd |
Kidney function
| ROA | GFR | Dosage | Interval | Comments |
|---|---|---|---|---|
| ROA: po | ||||
|
GFR: 30 - 50 |
Dosage: 50% van de standaarddosering |
|||
|
GFR: 10 - 30 |
Dosage: 30% van de standaarddosering |
|||
|
GFR: <10 |
Dosage: nucleoside-naïeve patiënten 0.05 mg 1 dd po of 0.5 mg elke 5-7 dagen. lamivudine-refractaire patiënten 0.5 mg elke 72 uur |
|||
Renal elimination:
75%
Dosage:
dependent on kidney function
Renal function-replacement therapy
CAPD: chronische hepatitis B met leverdecompensatie: 0,5 mg elke 72 uur. Met levercompensatie: zie FTK
Hemo dialysis: chronische hepatitis B met leverdecompensatie: 0,5 mg elke 72 uur. Met levercompensatie: zie FTK
CAV / VVHD: chronische hepatitis B met leverdecompensatie: 0,5 mg elke 72 uur. Met levercompensatie: zie FTK
Pregnancy
Due to the expiration of the alphanumeric classification for use in pregnancy and lactation, reference is made to the current, online information of the Teratology Information Service (TIS) of LAREB:
- http://www.lareb.nl//Teratologie/Naslagwerk-GZB/GZB---Zwangerschap#TOC_Middelen_bij6
- http://www.lareb.nl//Teratologie/Naslagwerk-GZB/GZB---Borstvoeding#TOC_Middelen_bij16
For individual advice, consult an expert on site.
Metadata
Swab vid: M-1909.2
Updated: 01/13/2020 - 15:40
Status: Published